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Abstract
Identification of variants in the acid α‐glucosidase (GAA) gene in Pompe disease
provides valuable insights and systematic overviews are needed. We report on the
number, nature, frequency, and geographic distribution of GAA sequence variants
listed in the Pompe Registry, a long‐term, observational program and the largest
global repository of Pompe disease data. Variant information was reviewed and
compared with publicly available GAA databases/resources. Among 1,079 eligible
patients, 2,075 GAA variants (80 unique novel) were reported. Variants were listed by
groups representing Pompe disease phenotypes. Patients were classified as Group A:
Symptom onset ≤ 12 months of age with cardiomyopathy; Group B: Symptom onset
≤ 12 years of age (includes patients with symptom onset ≤ 12 months of age without
cardiomyopathy); or Group C: Symptom onset > 12 years of age. Likely impact of
novel variants was predicted using bioinformatics algorithms. Variants were classified
by pathogenicity using ACMG guidelines. Data reported from the Pompe Registry
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provide new information about the distribution of GAA variants globally and across
the clinical spectrum, add to the number and diversity of GAA variants registered in
public databases through published data sharing, provide a first indication of the
severity of novel variants, and assist in diagnostic practice and outcome prediction.
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1 | INTRODUCTION
1.1 | Overview of Pompe disease
Pompe disease, also known as acid maltase deficiency and glycogen
storage disease type II (MIM# 232300), is a rare, progressive, autosomal
recessive inheritance (HP:0000007) disorder caused by deficient acid
α‐glucosidase (GAA), the lysosomal enzyme that breaks down glycogen.
Resulting abnormal accumulation of glycogen in lysosomes leads to
cellular dysfunction; progressive respiratory failure due to muscle
weakness (HP:0002740), cardiac anomalies (HP:0001626), abnormal
skeletal muscle morphology (HP:0004303), and damage to smooth
muscles with related functional disabilities; significant morbidity; and
premature age of death (HP:0011420) in many patients (Kishnani, Hwu
et al., 2006; Reuser, Hirschhorn, & Kroos, 2018; van der Ploeg & Reuser,
2008; van der Ploeg et al., 2017). While all patients eventually exhibit
progressive muscle weakness (HP:0003323), Pompe disease manifests as
a broad clinical spectrum of phenotypes with considerable variation in
age of symptom onset, presenting signs/symptoms, degree of severity,
organ involvement, and rate of progression. Patients with the most
severe form, classic infantile Pompe disease, have onset of symptoms
≤12 months of age, often within the first days to weeks of life, with
progressive cardiomyopathy (HP:0001638), decreased respiratory func-
tion due to muscle weakness (HP:0002747), muscle hypotonia
(HP:0001252), and death in infancy (between 1 and 2 years of age;
HP:0001522; Kishnani, Hwu et al., 2006; Reuser et al., 2018; van den
Hout et al., 2003). Cardiomyopathy is a cardinal feature of classic infantile
Pompe disease. In other patients, symptoms, including progressive
skeletal muscle weakness (HP:0040290) affecting mobility and leading
to respiratory failure (HP:0002093), evolve as a continuum of disease,
presenting as early as ≤12 months of age without significant cardiac
involvement, or later during early childhood through late adulthood,
sometimes as late as the 6th decade of life (Gungor & Reuser, 2013;
Kishnani & Howell, 2004; Montagnese et al., 2015; van der Ploeg &
Reuser, 2008). Across this continuum, patients can develop cardiac
manifestations in the first year but not the cardiomyopathy noted in
classic infantile Pompe disease (Slonim et al., 2000).
1.2 | The GAA gene and Pompe disease
The GAA gene is responsible for the production of GAA protein. The
occurrence of different pathogenic variants within the GAA gene causing
various levels of GAA enzyme deficiency and abnormal enzyme activity
(HP:0012379) influences disease severity and manifestations across the
disease spectrum and is a primary contributing factor to the considerable
variation seen in age of presentation, severity, and rate of progression
(M. Kroos, Hoogeveen‐Westerveld, van der Ploeg, & Reuser, 2012;
M. Kroos et al., 2008; M. A. Kroos et al., 2007; Montagnese et al., 2015;
Montalvo et al., 2006). Complete deficiency of the GAA enzyme, resulting
in enzyme activity < 1% of normal, is associated with classic infantile
Pompe disease. Residual enzyme activity is more variable in other patient
groups, and generally is not more than 30% of normal (Kishnani & Hwu,
2017; van der Ploeg & Reuser, 2008). To date, more than 400 pathogenic
variants, in addition to numerous benign variants and variants of
unknown significance (VUS), in the GAA gene have been reported
(ClinVar, 2017; Erasmus MC University Medical Center, 2017; Exome
Aggregation Consortium (ExAC), 2017; Genome Aggregation Database
(gnomAD), 2017; Leiden Open Variation Database (LOVD), 2018; The
Human Genome Mutation Database (HGMD), 2017). Confounding
genetic and nongenetic factors not yet identified seem to contribute to
the clinical diversity seen in phenotypes, including among family members
with the same pathogenic GAA genotypes (De Filippi et al., 2014;
M. A. Kroos et al., 2007; Slonim et al., 2007; Wens et al., 2013). A
common aspect for these patients is the presence of at least one variant
supporting the production of some residual GAA activity.
Identification of variants in the GAA gene provides valuable
information for confirming diagnosis or carrier status; determining
variant‐phenotype and genotype–phenotype correlations; and genet-
ic counseling. In addition, when standard biochemical assays are not
available, sequence variant identification may be used to predict
cross‐reactive immunologic material (CRIM) status, which can
influence treatment decisions (Bali et al., 2012; Kishnani et al., 2010).
1.3 | The Pompe Registry
The Pompe Registry is a long‐term, multinational, and observational
program (NCT002314000) designed to improve understanding of the
natural history and outcomes of patients with Pompe disease. It
started in 2004 and is sponsored and administered by Sanofi
Genzyme (Cambridge, MA). Patients with a confirmed diagnosis of
Pompe disease can be enrolled by physician investigators worldwide
regardless of age, clinical manifestations, or treatment status.
Participation by physicians and patients is completely voluntary.
Patients provide appropriate written informed consent for their
health information to be submitted to the Registry and for their data
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to be used in aggregate analyses. Treating physicians determine the
frequency and type of assessments according to the individual
patient's need for standard medical care and follow‐up. This detailed
patient information is collected in the Pompe Registry database.
Because of the voluntary and observational nature of the program,
the frequency and types of assessments reported for each patient
will vary. Physicians can report their patients’ characteristics,
including gender; age; clinical characteristics; and diagnostic para-
meters, including methods of diagnosis and the results of enzymatic
and genetic testing. The Pompe Registry can be accessed only by
participating physicians. In accordance with the consent provided by
patients, information gathered in the Pompe Registry can only be
shared to the general public through peer‐reviewed publications. This
is also the mechanism by which the Registry can provide information
for other genetic and phenotype databases. The Pompe Registry is
the largest global repository of data for Pompe disease and a
valuable resource for the medical community. Information on the
Registry can be found at https://www.registrynxt.com/ and also at
https://clinicaltrials.gov.
We have analyzed reported aggregate patient information in the
Pompe Registry to first determine the number, frequency, and
characteristics of all GAA sequence variants that were reported into
the Registry database as candidate disease‐associated variants among
patients diagnosed with Pompe disease on the basis of clinical features
and GAA deficiency. The present analysis is a foundational report and is
the first of a series of planned analyses on variant data from the Pompe
Registry. It focuses on the geographic distribution and frequencies of the
variants, including the novel, as yet unpublished, variants. While Pompe
disease is a clinical spectrum, analysis of the variant‐phenotype and
preliminary genotype–phenotype correlations is based on the assignment
of variants to three groups of patients characterized by age of symptom
onset with or without cardiomyopathy (HP:0001638).
2 | METHODS
2.1 | Patient eligibility
Patients with the following data in the Pompe Registry were eligible
for inclusion: Pompe disease diagnosis reported as confirmed by
enrolling physicians and with ≥ 1 documented pathogenic variant.
Patients were excluded if dates of diagnosis and/or symptom onset
were missing.
2.2 | Data collection of patient characteristics
and variant information
Demographic and clinical characteristics were collected on the
Registry's case report form (CRF). Whether patients were identified
through newborn screening was not part of this analysis. The CRF
does not provide information regarding methods for CRIM‐status
determination. Ethnicity and race are self‐reported on the CRF since
the Registry does not perform ancestry analyses to confirm what was
reported. General sibling information collected in the Registry is
reported. However, consanguinity is not collected and an analysis of
linked sibling data was not performed. GAA variant and phenotype
information from patient records in the Pompe Registry was
evaluated. Healthcare teams entering patient information at Registry
sites are instructed to enter the preferred c.DNA nomenclature in a
free text field in the Registry's CRF. Protein information is deduced
from c.DNA, but RNA information for variants is not collected by
the Registry.
2.3 | Informed consent and patient privacy
Each independent site is responsible for obtaining patients’ informed
written consent to submit their health information to the Registry,
and to use and disclose this information in aggregate analyses. The
Registry protocol, informed consent form, and any locally required
authorization documents to send patient information to the Registry
are reviewed and approved by the local fully constituted Institutional
Review Board (IRB) or Independent Ethics Committee (IEC) unless
the site provides the Registry with documentation that approval is
not required or has been waived by a particular IRB/IEC.
Informed consent is required to share patient data submitted to
the Pompe Registry. Therefore, only novel GAA variants for which
appropriate updated patient consent was available have been
submitted to the Single Nucleotide Polymorphism Database (dbSNP;
submission ID: SUB4205047; http://www.ncbi.nlm.nih.gov/SNP/) and
the Leiden Open Variation Database (LOVD; https://www.lovd.nl/).
2.4 | Variant nomenclature and standardization
Variant data are reported by individual sites, and errors and
discrepancies with how individual GAA sequence variants were
reported are possible. Variants also may be entered in different ways
as a result of variable interpunction, letter spacing, or software‐
directed automatic use of upper or lower case. Extensive reviews and
consultations with Registry sites were conducted and concerted
efforts made to standardize the nomenclature for the reported
variants to allow meaningful analyses and interpretation of results.
The Human Genome Variation Society (HGVS) recommenda-
tions were used to standardize nomenclature for variants reported
in the Registry (den Dunnen et al., 2016). For example, duplicated
nucleotides after the “dup” were excluded (e.g., "c.258dupC"
was standardized to "c.258dup"), as were deleted nucleotides
after the "del" (e.g., "c.1354_1372del19" was standardized to
"c.1354_1372del"). In addition, specified nucleotides were in-
cluded for all insertions and deletions/insertions (e.g., c.2741delins
was standardized to c.2741delinsGAC). Location in the GAA gene,
variant type, protein identifications for variants, and pathogenicity
for novel variants was predicted based on the c.DNA data available
in the Registry (see Acknowledgments and Supporting Informa-
tion). Identified variants that do not cause disease but that cause
low‐GAA activity when measured in enzyme assays, defined as
pseudodeficiency variants (Labrousse et al., 2010; Tajima et al.,
2007) are described. The following reference sequences were used
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to specify GAA variants: NM_000152.5 for the coding region
conform the Ensembl sequence of the forward strand on
Chromosome 17: 80,101,556‐80,119,879 [GRCh38:CM000679.2];
protein id [NP_000143.2], and intronic variants according to the
same gene locus Ensembl sequence [ENSG00000171298]
[LRG_673][NCBI Reference Sequence: NG_009822.1]
[NC_000017.10]. Relevant information can be readily accessed
via the HGNC Symbol report for GAA (HGNC 2018, 2018).
2.5 | Identification of novel variants
Variants were classified as “novel” if they were reported in the
Registry but not in the following publicly available sources: Current
listings in GAA variant databases (Duke University Medical Center,
2017; Erasmus MC University Medical Center, 2017) or other
sequence and variant databases (Exome Aggregation Consortium
(ExAC), 2017; Genome Aggregation Database (gnomAD), 2017;
Genome Project Consortium, 1000, 2017; Leiden Open Variation
Database (LOVD), 2018; NHLBI GO Exome Sequencing Project (ESP),
2017), public archives (ClinVar, 2017), database resources of the
National Center for Biotechnology Information (NCBI Resource
Coordinators, 2016), or through searches of other sources and
databases (including unpublished data; and data on file, Sanofi
Genzyme) through June 2017. Unique is defined here as meaning
different or distinct individual variants that were reported in the
Registry analysis data set. For example, if 25 reported variants are
c.525del and 7 are c.307T>G, then the number of reported variants is
32 and the number of unique variants reported is 2. All GAA variants
reported in this study (other than novel variants) are either linked with
Pompe disease http://www.pompecenter.nl (>molecular aspect-
s>Pompe variant database) or tentatively marked as candidate
disease‐associated variants as they were found in the DNA of patients
who were diagnosed with Pompe disease. Because the Registry CRF
does not inquire about the cis/trans occurrence of GAA variants and
also does not include confirmation of trans‐position by parent
investigation, the likely impact of novel variants was predicted using
bioinformatics algorithms, such as PROVEAN (Choi, Sims, Murphy,
Miller, & Chan, 2012), SIFT (Sim et al., 2012), PolyPhen (Adzhubei
et al., 2010), and FATHMM (Shihab et al., 2015). The programs were
deemed appropriate and chosen based on a number of criteria in the
ACMG Standards and Guidelines for Interpretation of Sequence
Variants (Richards et al., 2015) and Guidelines for Prediction Tools for
Genetic Variation Analysis (Vihinen, den Dunnen, Dalgleish, & Cotton,
2012). These methods are publicly available for research and were
chosen based on their proven performances. Also, as recommended,
because each sequence interpretation program has inherent strengths
and weaknesses and sensitivities depending on the algorithm used,
multiple predictive methods were used to decrease overpredictions
and increase more accurate conclusions and predictions of impact
(Vihinen et al., 2012; see Supporting Information online). Criteria for
classifying variants based on their severity scores and evidence of
pathogenicity (viz., benign, likely benign, variant of uncertain sig-
nificance [VUS], likely pathogenic, and pathogenic) as outlined in the
ACMG guidelines for the interpretation of sequence variants were
used for the classification of novel variants by predicted pathogenicity
(Richards et al., 2015). Variants could be classified as VUS due to
either insufficient evidence or conflicting evidence and are identified
as such. The effects of all previously published variants, as currently
listed in GAA variation databases, were not re‐analyzed.
2.6 | Patient phenotypic subgroup classification
Patients were classified into one of three groups based on the
reported age at first sign or symptom onset and reported the
presence or the absence of cardiomyopathy: Group A, onset of
symptoms ≤ 12 months of age with cardiomyopathy (patients
typically classified as classic infantile Pompe disease); Group B,
onset of symptoms ≤ 12 years of age (includes patients with onset of
symptoms ≤ 12 months of age without cardiomyopathy in the first
year of life and not included in Group A); and Group C, onset of
symptoms > 12 years of age. The presence of cardiomyopathy was
obtained from patient records as reported on the Registry CRF and
may not reflect the exact onset. The patient classifications were
based on the criteria described in previous Registry publications
(Kishnani et al., 2013, 2014) to allow for meaningful analysis,
interpretation, and explanation of results of the reported Registry
data. Clinical features of phenotypes were described using available
Human Phenotype Ontology (HPO) terms and identification numbers
(Kohler et al., 2019; The Human Phenotype Ontology (HPO), 2019).
To provide further clinically relevant information, homozygous
genotypes were used to further rate a subset of variants by degree of
severity.
2.7 | Statistical analyses
Descriptive statistics were used to summarize demographic and
variant information as this was a foundational report intended to
provide an initial overview of variants reported among patients in the
Pompe Registry. Thus, since there were no a priori hypotheses, no
formal inferential statistical tests were conducted. Frequencies
reported in 1 to < 5 patients are reported as < 5 to protect patient
privacy. All analyses were conducted using SAS 9.4 (SAS Institute
Inc., Cary, NC).
3 | RESULTS
3.1 | Demographics
As of July 2017, 1,753 consented patients were enrolled in the
Pompe Registry. Based on inclusion criteria, data were analyzed for
1,079 patients from 26 countries in five geographic regions (Europe,
North America, Asia‐Pacific, Latin America, and the Middle East).
Patient demographics and baseline characteristics are shown in
Table 1. Of note, patients from Latin America had to provide updated
consent for continued participation in the Registry. Therefore, only
the subset of enrolled Registry patients from Latin America with
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updated consent when data were collected (July 2017) are included.
Of the 1,079 patients with evaluable sequence variant information,
190 were classified as Group A, 238 as Group B, and 651 as Group C.
More than half (58.0%) of all patients were from Europe. The
majority (71.2%) were self‐reported as Caucasian. Overall, and for
each group, approximately half were female. Of the 257 patients
reported to have siblings diagnosed with Pompe disease, 26 were in
Group A, 43 in Group B, and 188 in Group C.
For Group A, mean age at symptom onset was 0.2 years (2.4
months) and mean age at diagnosis was 0.3 years (3.5 months). In
contrast, for Group B, mean age at symptom onset was 4.0 years
(median age: 2.2 years) and mean age at diagnosis was 13.9 years
(median age: 4.6 years), with a diagnostic gap between symptom
onset and a confirmed diagnosis of greater than 10 years for some
patients. Group C had a mean age at symptom onset of 36.5 years
and mean age at diagnosis of 42.8 years (Table 1).
Table 1 also lists the CRIM status of patients, whereby CRIM
indicates any form of GAA protein, catalytically active or inactive,
that is detected by immunologic procedures. Among the 135 Group A
patients with CRIM status reported, 95 (70.4%) were CRIM‐positive
and 40 (29.6%) were CRIM‐negative. CRIM status was unknown for
28.9% of the Group A.
3.2 | Variants and their geographic distribution
by group
A total of 2,075 (1,205 exonic/ 870 intronic) GAA variants were
reported among the 1,079 patients (Table 2). Of these, 392 variants
TABLE 1 Patient demographics and baseline clinical characteristics
All patients Group Aa Group Bb Group Cc
Patients, N 1,079 190 238 651
Geographic region
Europe 626 (58.0%) 67 (35.3%) 128 (53.8%) 431 (66.2%)
North America 343 (31.8%) 87 (45.8%) 77 (32.4%) 179 (27.5%)
Asia‐Pacific 93 (8.6%) 29 (15.3%) 29 (12.2%) 35 (5.4%)
Latin America 9 (0.8%) <5 <5 6 (0.9%)
Middle East 8 (0.7%) 5 (2.6%) <5 0
Number of countries 26 18 18 22
Race
Caucasian 768 (71.2%) 88 (46.3%) 165 (69.3%) 515(79.1%)
Black 42 (3.9%) 26 (13.7%) 5 (2.1%) 11 (1.7%)
Asian 97 (9.0%) 31 (16.3%) 37 (15.5%) 29 (4.5%)
Otherd 18 (1.7%) 7 (3.7%) 6 (2.5%) 5 (0.8%)
Unknown 154 (14.3%) 38 (20.0%) 25 (10.5%) 91 (14.0%)
Gender
Males 527 (48.8%) 92 (48.4%) 130 (54.6%) 305 (46.9%)
Females 552 (51.2%) 98 (51.6%) 108 (45.4%) 346 (53.1%)
Age at symptom onset (years)
Mean (SD) 23.0 (20.1) 0.2 (0.2) 4.0 (4.0) 36.5 (14.0)
Median (min, max) 20.4 (0.0,75.8) 0.2 (0.0,0.9) 2.2 (0.0,12.0) 36.9 (12.1,75.8)
Age at diagnosis (years)
Mean (SD) 28.9 (22.6) 0.3 (0.2) 13.9 (16.7) 42.8 (15.1)
Median (min, max) 32.1 (0.0,82.5) 0.3 (0.0,1.3) 4.6 (0.0,69.2) 43.0 (0.4,82.5)
CRIM status
CRIM positive, N (%) 175 (16.2%) 95 (50.0%) 38 (16.0%) 42 (6.5%)
CRIM negative, N (%) 42 (3.9%) 40 (21.1%) <5 0
CRIM unknown N (%) 862 (79.9%) 55 (28.9%) 198 (83.2%) 609 (93.5%)
Siblings diagnosed with Pompe disease (N) 257 26 43 188
Number diagnosed
1 186 22 31 133
2 44 <5 8 35
≥3 12 0 <5 11
Missing 15 <5 <5 9
Abbreviation: CRIM, cross‐reactive immunologic material.
Denominators of percentages are based on N values for each group (all patients: N = 1,079; Group A: N = 190; Group B: N = 238; Group C: N = 651) unless
otherwise specified. Frequencies reported in the Pompe Registry in fewer than five patients are reported as < 5 to protect patient privacy.
aGroup A: Onset of symptoms ≤ 12 months of age with cardiomyopathy (patients classified as classic infantile Pompe disease). Group A also may include a
subset of patients with less severe cardiomyopathy and slower disease progression.
bGroup B: Onset of symptoms ≤ 12 years of age (includes patients with onset of symptoms ≤ 12 months of age without cardiomyopathy and not included
in Group A).
cGroup C: Onset of symptoms > 12 years of age.
dNative Hawaiian or other Pacific Islander or multiple race categories.
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were unique (as defined in Methods), 80 being novel (Table 3), and
312 variants (Table S1) being known. Two or more variants were
reported in the large majority (n = 969) of patients (Table 2).
Nineteen patients (7 in Group A; 5 in Group B; and 7 in Group C)
had three variants reported, and four patients had four (2 in Group A;
and 1 in Groups B and C each). Among patients with two or more
variants were 17 with the common pseudodeficiency variant,
c.1726G>A frequently found in Asian populations (M. A. Kroos
et al., 2008; Kumamoto et al., 2009; Yang et al., 2011) and < 5 with
the pseudodeficiency allele c.271G>A, frequent in Caucasians
(Swallow et al., 1989; van Diggelen et al., 2009; data not shown).
Only one variant was reported in the Registry for 110 patients:
18 in Group A, 24 in Group B, and 68 in Group C (Table 2). Among
these 110 patients, diagnosis was reported to have been made by a
combination of DNA analysis and GAA enzyme assays, which include
measurement of enzyme activity in blood‐based assays (lymphocytes
TABLE 2 Frequency of variants among patients with variant information by phenotypic subgroups
Parameter All patients Group Aa Group Bb Group Cc
Number of variants, Nd,e 2,075 373 459 1,243
Novel variants, N (%)f 94 (4.5%) 18 (4.8%) 17 (3.7%) 59 (4.7%)
Unique novel variants,e,f N (%) 80 (3.9%) 17 (4.6%) 16 (3.5%) 49 (3.9%)
Known variants, N (%)e 1,981 (95.5%) 355 (95.2%) 442 (96.3%) 1,184 (95.3%)
Unique known variants, N (%) 312 (15.0%) 135 (36.2%) 146 (31.8%) 196 (15.8%)
Patients with any variant entry, N 1,079 190 238 651
Patients with ≥2 variant entries, Nd 969 172 214 583
Patients with 1 variant entry, N 110 18 24 68
aGroup A: Onset of symptoms ≤ 12 months of age with cardiomyopathy (patients typically classified as having classic infantile Pompe disease). Group A
also may include a subset of patients with less severe cardiomyopathy and slower disease progression.
bGroup B: Onset of symptoms ≤ 12 years of age (includes patients with onset of symptoms ≤ 12 months of age without cardiomyopathy and not included
in Group A).
cGroup C: Onset of symptoms > 12 years of age.
dSome patients have a combination of more than 2 variants.
eKnown variants are defined as having been previously published or identified as described in the Methods section. Unique is defined here as meaning
different or distinct individual variants. The N is based on the total number of variants. Denominators for percentages are based on the total numbers of
variants per patient groups (e.g., in Group A, 355 of known variants represent 95.2% of the total variants in this group).
fVariants are classified as “novel” if they are reported in the Pompe Registry but not previously published or identified in publicly available sources
(as described in the Methods) as of June 2017.
TABLE 3 Unique novel variants reported among patients by phenotypic subgroups
Location DNA Proteina
Phenotypic
subgroupb
Predictionc
PathogenicitydSIFT
Polyphen‐2
HVAR
FATHMM
MKL
exon2 c.295_314del p.(Thr99ProfsTer40) C Pathogenic
exon2 c.541_545del p.(Phe181AspfsTer6) A Pathogenic
exon3 c.665T>G p.(Val222Gly) A D PD D VUS – insufficient evidence
exon3 c.686G>C p.(Arg229Pro) C T B T VUS – insufficient evidence
exon3 c.692T>C p.(Leu231Pro) C D PD D VUS – insufficient evidence
intron3 c.692+1G>T p.? C NA NA D Pathogenic
intron3 c.693‐2A>C p.? A NA NA D Pathogenic
exon4 c.759del p.(Ser254ArgfsTer14) C Pathogenic
exon4 c.766_784del p.(Tyr256SerfsTer6) B Pathogenic
exon5 c.878G>T p.(Gly293Val) C D PD D Likely pathogenic
exon5 c.930_932del p.(Phe311del) A VUS – Conflicting evidence
exon5 c.950C>T p.(Ala317Val) B D PD D VUS – conflicting evidence
exon6 c.982_988del p.(Leu328GlyfsTer62) A Pathogenic
exon6 c.994_995insTT p.(Ser332PhefsTer61) C Pathogenic
exon6 c.1005_1006insGG p.(Ile336GlyfsTer57) C Pathogenic
exon6 c.1057C>T p.(Gln353Ter) C NA NA D Pathogenic
(Continues)
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TABLE 3 (Continued)
Location DNA Proteina
Phenotypic
subgroupb
Predictionc
PathogenicitydSIFT
Polyphen‐2
HVAR
FATHMM
MKL
exon7 c.1109G>A p.(Gly370Asp) C D PD D VUS – conflicting evidence
exon7 c.1114C>G p.(His372Asp) C D PD D Likely pathogenic
exon7 c.1114C>T p.(His372Tyr) C D PD D Likely pathogenic
exon7 c.1121G>A p.(Cys374Tyr) C D PD D Likely pathogenic
exon7 c.1127_1130del p.(Trp376SerfsTer15) B Pathogenic
exon7 c.1129G>A p.(Gly377Ser) B D PD D Likely pathogenic
exon8 c.1201C>A p.(Gln401Lys) C D PD D VUS – insufficient evidence
exon8 c.1211A>C p.(Asp404Ala) B D PD D Likely pathogenic
exon8 c.1211A>T p.(Asp404Val) A D PD D Likely pathogenic
exon8 c.1231del p.(Arg411GlyfsTer29) B Pathogenic
exon8 c.1242C>A p.(Phe414Leu) C D PD D VUS – insufficient evidence
exon8 c.1311_1312ins26 NA A Pathogenic
exon9 c.1378G>T p.(Glu460Ter) C NA NA D Pathogenic
exon9 c.1388_1406del p.(Arg463ProfsTer8) C Pathogenic
exon9 c.1396dup p.(Val466GlyfsTer40) C Pathogenic
exon9 c.1409A>G p.(Asn470Ser) C D PD D VUS – insufficient evidence
exon10 c.1477C>T p.(Pro493Ser) B D PD D VUS – insufficient evidence
exon10 c.1507del p.(Val503TrpfsTer17) A Pathogenic
exon10 c.1526A>T p.(Gln509Leu) C T PD D VUS – insufficient evidence
intron10 c.1551+3A>T p.? C VUS – insufficient evidence
exon11 c.1559A>G p.(Asn520Ser) C D PD D VUS – insufficient evidence
exon12 c.1670T>G p.(Ile557Ser) C D PD D Likely pathogenic
exon12 c.1681_1699dup p.(Thr567LysfsTer75) C Pathogenic
exon12 c.1688A>T p.(Gln563Leu) C D PD D Likely pathogenic
exon12 c.1721T>C p.(Leu574Pro) C D PD D VUS – insufficient evidence
intron12 c.1754+1dup p.? C Pathogenic
exon13 c.1822del p.(Arg608AspfsTer88) C Pathogenic
exon13 c.1825T>G p.(Tyr609Asp) C D PD D Likely Pathogenic
exon13 c.1839 G>C p.(Trp613Cys) B D PD D VUS – insufficient evidence
exon13 c.1847dup p.(Asp61GlufsTer20) C Pathogenic
exon13 c.1876_1878del p.(Ser627del) C VUS – insufficient evidence
exon14 c.1895T>C p.(Leu632Pro) C D PD D VUS – insufficient evidence
exon14 c.1944_1950del p.(Phe649AlafsTer45) B,C Pathogenic
exon14 c.1961C>G p.(Ser654Ter) C NA NA T Pathogenic
exon14 c.2004C>A p.(Tyr668Ter) A NA NA D Pathogenic
exon14 c.2020C>T p.(His674Tyr) C D PD D VUS – insufficient evidence
intron14 c.2041‐2A>G p.? A Pathogenic
exon15 c.2056_2057 delinsCC p.(Ser686Pro) A T B T VUS – insufficient evidence
exon15 c.2084dup p.(Met695IlefsTer70) C Pathogenic
exon15 c.2096T>C p.(Leu699Pro) A D PD D VUS – insufficient evidence
exon15 c.2109del p.(Tyr703Ter) C Pathogenic
exon15 c.2146G>C p.(Ala716Pro) B D PD D VUS – conflicting evidence
(Continues)
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and leukocytes), fibroblasts, and skeletal muscle tissue in most
(82.7%) patients and by DNA analysis only in 17.3% of patients.
Table 4 provides an overview of the five most common
variants across the clinical spectrum by patient group globally and
regionally as reported in the Pompe Registry. Globally, eight
different variants represent most of the reported variants. Two of
these eight variants (c.525del and c.2481+102_2646+31del) are
not group‐specific, and Groups B and C share the same common
variants. Among Group A, the variant c.2560C>T is the most
common globally and in both North America and Latin America
and is among the five most common in Europe but not in Asia‐
Pacific and the Middle East. The variant c.1935C>A was the
second most common globally and the most common in Asia‐
Pacific but was not frequently reported in any other region. Also,
in Groups B and C, c.‐32‐13T>G is the most commonly reported
variant globally as well as in Europe and North America, and in
Group C only in Latin America, but not in Asia‐Pacific and the
Middle East.
Other variants predicted to affect correct splicing or causing in‐
frame smaller or larger structural changes (encompassing 1–54 amino
acids) were equally frequent in all three groups (data not shown). The
functional impact of most novel variants cannot be foreseen. This is
true for missense variants, small in‐frame deletion or insertion variants,
and variants in or near splice sites that have either no effect, a partial
effect, or a detrimental effect on GAA synthesis and function. The
ACMG guidelines for classifying the novel variants based on severity
were followed (see section 3.3 novel variants for results). For severity
rating one can cautiously, in parallel, also build on the phenotype of the
patients in which the variants were found. Thus, we have listed all
individual variants reported in Group A in a separate Table 5. Each
variant reported in Table 5 likely contributes to the classic infantile
Pompe disease phenotype and is potentially very severe.
TABLE 3 (Continued)
Location DNA Proteina
Phenotypic
subgroupb
Predictionc
PathogenicitydSIFT
Polyphen‐2
HVAR
FATHMM
MKL
exon15 c.2153_2156delin-
sACGCCG
p.(Val718AspfsTer47) B T B T Pathogenic
exon15 c.2182_2183del p.(Phe728ProfsTer8) C Pathogenic
exon16 c.2205_2206insT p.(Ser736Ter) C Pathogenic
exon16 c.2237G>T p.(Trp746Leu) B D PD D Likely pathogenic
exon16 c.2240G>A p.(Gly747Glu) C D PD D VUS – insufficient evidence
exon16 c.2258_2259insC p.(Val755SerfsTer41) C Pathogenic
exon16 c.2261dup p.(Val755LysfsTer10) C Pathogenic
intron16 c.2331+101del p.? C VUS – conflicting evidence
exon17 c.2407C>T p.(Gln803Ter) C NA NA D Pathogenic
exon17 c.2459_2461del p.(Ala820del) A,C VUS – conflicting evidence
exon17 c.2460dup p.(Gly821TrpfsTer63) B Pathogenic
exon18 c.2480A>G p.(Gln827Arg) B D PD D VUS – insufficient evidence
exon18 c.2515C>T p.(Gln839Ter) A NA NA D Pathogenic
exon18 c.2584G>A p.(Gly862Arg) B D PD D VUS – insufficient evidence
exon18 c.2619C>G p.(Tyr873Ter) C NA NA D Pathogenic
exon19 c.2655_2656del p.(Val886GlufsTer2) C Pathogenic
exon19 c.2720T>C p.(Leu907Pro) B D PD D VUS – insufficient evidence
exon19 c.2740dup p.(Gln914ProfsTer104) A Pathogenic
exon19 c.2742dup p.(Gln915AlafsTer103) A Pathogenic
exon19 c.2757del p.(Asn919LysfsTer24) C Pathogenic
intron19 c.2800‐1G>C p.? A NA NA D Pathogenic
exon20 c.2845_2847del p.(Val949del) C VUS – insufficient evidence
Abbreviations: B, benign; D, damaging; PD, probably damaging; T, tolerated; NA, information not available.
aThe protein is provided where data are available. p.? is used to indicate that the impact on the protein is not known.
bGroup A: Onset of symptoms ≤ 12 months of age with cardiomyopathy (patients classified as classic infantile Pompe disease) [Group A also may include a
subset of patients with less severe cardiomyopathy and slower disease progression]; Group B: Onset of symptoms ≤ 12 years of age (includes patients
with onset of symptoms ≤ 12 months of age without cardiomyopathy and not included in Group A); Group C: Onset of symptoms > 12 years of age.
cVariants without Sift, Polyphen‐2 HVAR, or FATHMM‐MKL signature were not investigated as the nature of the variant predicted a damaging effect in
all cases.
dPathogenicity is based on criteria for severity provided in the ACMG guidelines for interpretation of sequence variants (Richards et al., 2015).
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3.3 | Novel variants
There were 94 (4.5%) novel variants reported (18 in Group A, 17 in
Group B, and 59 in Group C). Of these, 80 are unique (Tables 2,3).
Most novel variants were reported in patients in Europe (66.7%) and
North America (20.0%). As seen in Figure 1, these unique novel
variants were located throughout the GAA gene (73 in exons; 7 in
introns). All variant types were represented. Overall, substitution
(missense) was the most frequent type of variant reported among the
three groups, accounting for 40.0% (n = 32) of the 80 unique novel
variants, followed by frameshift variants (33.8%; n = 27). Without
knowing the precise impact of these variants on GAA function, there
is good reason to assume that the majority of the novel variants have
a pathogenic effect since they were identified in patients diagnosed
with Pompe disease in absence of other known sets of disease‐
causing GAA variants.
In addition, the impact of the novel variants was preliminarily
predicted using the validated programs (Richards et al., 2015;
Vihinen et al., 2012), SIFT, PolyPhen, or FATHMM for 47 of the
80 unique novel variants for which impact was not evident from
their nature (Table 3; Supporting Information). The predicted
pathogenicity based on the ACMG criteria for severity and impact
(where available) for the 80 unique novel variants are reported in
Table 3. Overall, 51.3% (n = 41) of the 80 variants were classified as
pathogenic, 13.8% (n = 11) as likely pathogenic, and 35% (n = 28) as
VUS. Of the 17 unique novel variants reported for Group A,
11 were classified as pathogenic, one as likely pathogenic, and five
as VUS (Table 3). Among these 17 unique novel variants reported
for Group A, frameshift variants were the most common type
(35.3%; n = 6). Of these variants, two (c.541_545del and
c.982_908del), present in exons 2 and 6, respectively, mapped to
the N Terminal Beta Sheet domain; one (c.1507del) mapped to the
catalytic GH31 domain; and two (c.2740dup and c.2742dup)
mapped to the Distal Beta Sheet domain. Only one
(c.1311_1312ins26), present at exon 8, mapped to the catalytic
GH31 domain just before the start of insert 1 in the translated
protein. No predictions of impact were available for these frame-
shift variants using bioinformatics algorithms. However, all were
classified as pathogenic based on the ACMG's severity scores.
Other variant types were reported in < 5 patients in Group A.
Deletion (small) variants mapped to the N terminal Beta
Sheet domain (c.930_932del), the catalytic GH31 domain
(c.2056_2057del), and the Proximal Beta Sheet (c.2459_2461del,
also present in Group C). All three variants were classified as VUS
based on the ACMG guidelines. Splicing variants mapped to the N
Terminal GH31 domain (c.693‐2A>C), the catalytic GH31 domain
(c.2041–2A>G), and the Distal Beta Sheet (c.2800–1G>C). Sub-
stitution (missense) variants mapping to the N terminal Beta Sheet
domain were predicted to be damaging by SIFT and FATHMM and
probably damaging by Polyphen (c.665T>G). Three of these four
variants (c.693–2A>C, c.2041–2A>G, and c.2800–1G>C) were
predicted to be pathogenic; the fourth, c.665T>G was classified
as VUS per the ACMG severity scoring. Those mapping to the
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catalytic GH31 domain (c.1211A>T and c.2096T>C) were predicted
to be damaging by SIFT and FATHMM and probably damaging by
Polyphen. As noted in Table 3, c.1211A>T was classified as likely
pathogenic, and c.2096T>C as VUS. Substitution (nonsense)
variants mapping to the catalytic GH31 domain (c.2004C>A) and
Distal Beta Sheet (c.2515C>T) were both not predicted by SIFT and
Polyphen but were predicted as damaging by FATHMM. Per the
ACMG criteria, both variants were classified as pathogenic.
TABLE 5 All variants reported among patients within Group A in the Pompe Registry
Location DNA
intron1 c.‐32–17_‐32–10delinsTCCCTGCTGAGCCTCCTACAGGCCTCCCG
exon2 c.40_47del; c.236_246del; c.258dup; c.266G>A; c.307T>G; c.340_341insT; c.352C>T; c.378_379del;
c.525_526del; c.525del; c.541_545del
intron2 c.546+2_5del
exon3 c.572A>G; c.655G>A; c.665T>G; c.670C>T
intron3 c.693‐2A>C
exon4 c.716del; c.722_723del; c.784G>A; c.794del; c.854C>G
exon5 c.871C>T; c.872T>C; c.877G>A; c.925G>A; c.930_932del; c.947A>G; c.953T>C
exon6 c.982_988del; c.1000G>T; c.1062C>G; c.1064T>C
intron6 c.1075+13C>T
exon7 c.1082C>T; c.1099T>C; c.1115A>T; c.1129G>C; c.1157dup; c.1190C>T
intron7 c.1195–2A>G
exon8 c.1197_1208del; c.1210G>A; c.1211A>G; c.1211A>T; c.1221C>A; c.1281G>T; c.1286A>G;
c.1311_1312ins26
exon8–15 c.1195‐18_2190‐20del
intron8 c.1327‐2A>G
exon9 c.1396G>T; c.1396del; c.1402A>T; c.1408_1410del; c.1411_1414del
intron9 c.1437+1G>A; c.1437+2T>C; c.1438–1G>C
exon10 c.1441T>C; c.1441del; c.1447G>A; c.1465G>A; c.1466A>G; c.1496G>A; c.1507del; c.1548G>A
intron10 c.1551+1G>T
exon11 c.1561G>A; c.1564C>G; c.1564C>T
intron11 c.1637–2A>G
exon12 c.1642G>T; c.1650dup; c.1654del; c.1655T>C; c.1703A>T; c.1705dup; c.1724A>C; c.1726G>Aa; c.1735G>A
intron12 c.1754+1G>A; c.1754+2T>A
exon13 c.1796C>A; c.1798C>T; c.1799G>A; c.1802C>G; c.1802C>T; c.1822C>T; c.1841C>A
c.1843G>A; c.1844G>A; c.1846G>A; c.1880C>T
exon14 c.1912G>T; c.1913G>A; c.1927G>A; c.1933G>A; c.1933G>C; c.1933G>T; c.1935C>A; c.1941C>G; c.1942G>A; c.1962_1964del;
c.1979G>A; c.2004C>A; c.2015G>A; c.2023_2025del; c.2024_2026del; c.2040G>A
intron14 c.2041‐2A>G
exon15 c.2051C>T; c.2056_2057delinsCC; c.2078dup; c.2096T>C; c.2104C>T; c.2105G>T; c.2173C>T
exon16 c.2219_2220del; c.2227C>T; c.2236T>C; c.2237G>A; c.2238G>A; c.2274dup; c.2294G>A; c.2296T>A; c.2297A>C; c.2303C>T
intron16 c.2331+1G>A; c.2331+2T>A
exon17 c.2408_2426del; c.2459_2461del
intron17 c.2481+102_2646+31del
exon 18 c.2495_2496del; c.2501_2502del; c.2512C>T; c.2515C>T; c.2528T>C; c.2560C>T; c.2608C>T
intron18 c.2646+2T>A
exon19 c.2662G>T; c.2707_2709del; c.2740dup; c.2741delinsGAC; c.2742dup; c.2770T>C
intron19 c.2800‐1G>C
exon20 c.2815_2816del; c.2841_2842insT; c.2846T>A
Note. Variants in boldface indicate novel variants. They were reported in the Registry but not reported in the publicly available sources (see Methods)
identified as of June 2017.
ac.1726G>A is a well‐known pseudodeficiency variant and is linked to other variants (see main text).
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Of the 16 unique novel variants reported for Group B, six were
classified as pathogenic, three as likely pathogenic, and seven as
VUS (Table 3). Two variant types comprised all 16 unique novel
variants reported in Group B: substitution (missense) variants
(62.5%; n = 10) and frameshift (37.5%; n = 6). Among the 49 unique
novel variants for Group C, 25 were classified as pathogenic,
seven as likely pathogenic, and 17 as VUS (Table 3). The most
frequent types were substitution (missense) variants (38.8%;
n = 19) and frameshift (32.7%; n = 16). Table S1 describes the
distribution of previously published (nonnovel) variants by the
patient phenotypic subgroup. Of the 80 unique novel variants, 53
had appropriate patient consent and were entered into dbSNP
(submission ID SUB4205047; http://www.ncbi.nlm.nih.gov/SNP/)
and the Leiden Open Variation Database (LOVD; https://www.
lovd.nl/; Table S2).
3.4 | Homozygous patients
Homozygous patients are readily informative for genotype–phe-
notype analysis. Among 172 patients in Group A with ≥ 2
identified variants, 56 (32.6%) patients were homozygous
(Table 6). Of these patients, 53.6% were CRIM‐positive and
44.6% were CRIM‐negative. Among patients with ≥ 2 identified
variants in Groups B (n = 214) and C (n = 583), 12 (5.6%) and 17
(2.9%), respectively, were homozygous (Table 6). Notably, three
homozygous variants (c.1843G>A, c.1933G>A, and c.1935C>A)
F IGURE 1 Location of novel variants in the GAA gene. (a) GAA gene with novel variants reported in the Pompe Registry. Variant listings are
color coded to identify corresponding domain in the GAA protein (panel c). Variants listed in black text are either intronic or have no apparent
protein‐level change. (b) GAA mRNA. (c) GAA protein
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were reported in both Groups A and B, and one
(c.2481+102_2646+31del) in both Groups A and C.
4 | DISCUSSION
4.1 | Summary
We analyzed data for 1,079 patients with GAA gene variants across
five geographic regions and 26 countries, as entered in the Pompe
Registry, a long‐term, ongoing, multinational, and observational
program. A total of 2,075 variants spanning most of the GAA gene
were reported, with the exceptions of exon 1 (noncoding), deep
intronic regions, and promoter and regulatory gene regions. For such
reasons, GAA sequence analysis results may not always inform the
entirety of genetic contribution.
Of 2,075 variants reported in the Pompe Registry, 80 unique
variants were novel, according to extensive review and standardiza-
tion of nomenclature following the HGVS guidelines (den Dunnen
et al., 2016) that allow meaningful sharing and interpretation of
results (den Dunnen et al., 2016; Duke University Medical Center,
2017; Erasmus MC University Medical Center, 2017; Exome
Aggregation Consortium (ExAC), 2017; Genome Aggregation Data-
base (gnomAD), 2017; Genome Project Consortium, 1000, 2017;
NHLBI GO Exome Sequencing Project (ESP), 2017; The Human
Genome Mutation Database (HGMD), 2017). Reporting these novel
variants is especially relevant for the prediction of phenotypes
TABLE 6 Variants reported in homozygosity for patients by phenotypic subgroup across the clinical spectrum of Pompe disease
Group A by CRIM status (N = 56 patients)a
Group B (N = 12 patients)b Group C (N = 17 patients)cCRIM‐positive (n = 30) CRIM‐negative (n = 25)
c.307T>G c.340_341insT c.‐32‐13T>G c.‐32‐13T>G (n=13)
c.655G>A c.525_526del c.670C>T c.‐32‐3C>A
c.877G>A c.525del c.1064T>C c.‐32‐3C>G
c.925G>A c.1195‐18_2190‐20del c.1437G>A c.1076‐22T>G
c.1195‐2A>G c.1496G>A c.1447G>A c.2481+102_2646+31deld
c.1210G>A c.1637‐2A>G c.1843G>Ae
c.1561G>A c.2237G>A c.1933G>Ae
c.1564C>G c.2495_2496del c.1935C>A
c.1726G>A c.2560C>T c.2530_2541del
c.1799G>A c.2608C>T c.2744A>C
c.1843G>A c.2662G>T
c.1844G>A c.2740dup
c.1933G>A c.2741delinsGAC
c.1933G>C c.2742dup
c.1935C>A (n=7)
c.1942G>A
c.2015G>A
c.2104C>T
c.2297A>C
c.2481+102_2646+31del
CRIM unknown
c.2078dup
Note: Frequencies of each variant are < 5, except where noted. Some variants were reported in more than 1 patient, and therefore the total numbers of
variants listed in the table are less than the number of patients in each group.
aGroup A: Onset of symptoms =?12 months of age with cardiomyopathy (patients classified as classic infantile Pompe disease). Group A also may include a
subset of patients with less severe cardiomyopathy and slower disease progression.
bGroup B: Onset of symptoms =?12 years of age (includes patients with onset of symptoms =?12 months of age without cardiomyopathy and not included
in Group A).
cGroup C: Onset of symptoms >?12 years of age.
dThe reporting of this variant in Group C, which is typically found in Group A, may reflect that the information was entered incorrectly in the Registry or
may be the result of a technical error in the genetic analysis.
eGroup classification is based on age of symptom onset and reported the presence of cardiomyopathy (as described above). Any delays in cardiac
assessment or diagnosis could lead to a misclassification. These patients appear to have been misclassified, most likely due to the date that cardiac
assessments were requested and/or results recorded in the Registry. If this happened after the cutoff age for Group A (=?12 months of age), then the
patient would be analyzed as Group B.
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associated with these variants. While our manuscript was in
preparation, 11 of these 80 novel variants appeared in a report on
GAA variants discovered in French patients with Pompe disease
(Semplicini et al., 2018).
With regard to the severity of GAA variants, those identified in
Group A (Table 5) are “very severe” as they were found in patients
with very early onset of first symptoms (The Human Phenotype
Ontology (HPO), 2019) and cardiomyopathy (HP:0001638), that is,
patients with classic infantile Pompe disease. Homozygosity for any
of these variants is expected to lead to this phenotype, and this
expectation is largely confirmed by the data on homozygous
genotypes presented in Table 6.
The homozygous variants in Groups B and C are group‐specific,
except for the most common c.‐13‐32T>G variant, which is known to
be associated with a very broad clinical spectrum (M. Kroos et al.,
2012; M. Kroos et al., 2008; M. A. Kroos et al., 2007; Montalvo et al.,
2006; Semplicini et al., 2018). While we recognize and acknowledge
apparent discrepancies in the reported data across the three
phenotypic subgroups, these generally were not very many overall
and were not sufficient to impact our conclusions.
This genotype–phenotype analysis has predictive value for a
much larger group of patients. Not only homozygosity, but also
compound heterozygosity in any combination of Group A variants
(Table 5) will in principle be associated with the classic infantile
phenotype. Variants that occur in Groups B and C in compound
heterozygosity with a Group A variant will in principle be associated
with less severe and less progressive phenotypes than those
encountered in Group A. These suppositions have to be confirmed
by future genotype–phenotype analyses.
Other than through analysis of genotype–phenotype correlations,
the severity of variants can also be deduced from functional studies
and in silico prediction. Functional studies were performed in the
past (M. Kroos et al., 2012; M. Kroos et al., 2008; Montalvo et al.,
2006). Because they could not be performed in the context of this
study, in silico prediction programs were used to analyze the effect of
all novel variants without obvious effect (variants causing frame-
shifts, those introducing premature stop codons, and those within
position −2 to +2 of splice sites were taken as damaging). Using these
programs, all but four novel variants were scored as damaging by at
least one, but in the majority by two, prediction programs (see
Table 3 and Supporting Information). As expected based on
genotype‐phenotype correlation, the novel variants in Group A were
scored as damaging by at least one of the prediction programs,
including the two substitution (missense) variants c.665T>G that
mapped to the N terminal Beta Sheet domain of the protein and
c.1211A>T that mapped to the catalytic GH31 domain. As shown in
Table 3, the c.665T>G variant was classified as VUS (due to
insufficient evidence) and c.1211A>T as likely pathogenic. The only
discrepancy found was c.2056_2057delinsCC, which resulted in a
predicted substitution at the protein level (p.(Ser686Pro)) and
mapped to the catalytic GH31 domain of the protein. The impact
of this variant was predicted as tolerable with both SIFT and
FATHMM and benign using PolyPhen. This is unexpected since this
variant was identified in Group A, the most severe disease category,
and the introduction of a proline for a serine is likely to affect the
protein folding especially since the particular substitution is mapping
to the catalytic domain of the protein. For this one particular variant,
the prediction appears to have failed, that is, no correlation could be
made between the predicted severity and a phenotype. In addition,
this variant was classified as VUS (due to insufficient evidence) based
on ACMG severity scores. Of the remaining variants, two substitu-
tion (missense) variants — c.686G>C mapping to the N terminal Beta
Sheet domain and c.1526A>T mapping to the catalytic GH31 domain
and predicted to be possibly not damaging by preliminary in silico
analysis — were from patients in Group C. Both of these variants
were classified as VUS (due to insufficient evidence). Also, the
nonsense variant c.1961C>G and the frameshift variant
c.2153_2156delinsACGCCG both mapped to the catalytic GH31
domain. They were identified in Group C and Group B, respectively.
The predicted tolerability of the two missense variants might be
relevant with regard to the phenotype of the patients in which they
were found. Tolerability of the nonsense and frameshift variants
seems very unlikely. In addition, both variants were classified as
pathogenic when scored using the ACMG guidelines. It is possible,
therefore, that the second allelic variant of these patients may
account for the Group B and Group C phenotypes. The predictions
provided here were the initial preliminary look at the novel variants.
Genotype‐phenotype analysis, functional analysis, and more detailed
in silico analysis in accordance with the existing guidelines (Richards
et al., 2015; Vihinen et al., 2012) are required to properly report and
interpret these prediction results and will be part of future
publications. However, this approach showed consistency in the in
silico preliminary analysis matching to phenotype subgroup classifi-
cations for all prediction but one. Based on current insight and using
the ACMG guidelines for variant classification by severity scores, we
were able to predict the pathogenicity of 52 of the 80 unique novel
variants. Of these 52 variants, 79% (n = 41) were scored as
pathogenic and 21% (n = 11) as likely pathogenic. The remaining 28
variants were scored as VUS (due to either insufficient or conflicting
evidence; Table 3).
It may be difficult to estimate the severity of variants for a
number of reasons, including if their natures does not allow for this,
which is the case for most intronic variants; if functional studies are
lacking, particularly for substitution (missense) variants; if in silico
predictions are multi‐interpretable; if the GAA activity of the patient
and the clinical signs are borderline normal/abnormal; and if a second
damaging variant is not detected. One or more of these situations
may apply to the 1,079 cases that were entered in the Registry and
analyzed in this study. The 110 (10.1%) patients with just one variant
reported deserve special mention. Among these patients, diagnosis
was reported to have been made by a combination of DNA analysis
and GAA enzyme assays in most patients (82.7%) and therefore the
second variant may be missing because only standard sequencing
techniques are commonly used in most countries. Further testing
such as copy number variation (CNV) analysis using techniques
sensitive enough to determine small duplications and deletions
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within exons and regulatory regions of the GAA gene, such as
quantitative polymerase chain reaction (qPCR) or paralog ratio
testing (PRT), are not done routinely. In addition, GAA mRNA assay
that would allow detection of other types of variants such as deep
intronic variants also is not performed by many laboratories.
However, the importance of finding two variants to confirm Pompe
disease diagnosis is recognized, and current initiatives to improve
testing are underway, mainly through academic collaboration.
Increased efforts to expand this and incorporate it into standard
practice, for example, through the issuance and updating of guide-
lines, such as those from the European Pompe Consortium (EPOC;
van der Ploeg et al., 2017), are needed. Nineteen of the 110 patients
with just one variant were reported to have been diagnosed based on
clinical signs and DNA analysis only and not by GAA enzyme assay.
Although these patients were reported to have Pompe disease, their
GAA level was not reported and we therefore cannot be certain how
their diagnosis was confirmed. While all patients enrolled in the
Pompe Registry must have a reported confirmed Pompe disease
diagnosis (see Methods), we acknowledge the possibility of the
presence of a second, unidentified or unrecorded pathogenic variant
or of misdiagnosed carriers. Likewise, additional unidentified
pathogenic or unrecorded variants may be present in cases where
there were discordant results regarding the groupings of patients.
Misdiagnosis may also play a role in the differentiation between
Group A and B patients. While age of onset of symptoms is the basis
of patient classification in our analysis, it is not the sole discriminat-
ing factor for the patient phenotypic subgroups. Rather, the presence
of cardiomyopathy in patients under the age of 1 year is the
distinguishing feature. We cannot exclude that Group A may include
a subset of patients with less severe cardiomyopathy and slower
disease progression and Group B a subset of patients with a delayed
diagnosis of cardiomyopathy as previously reported in the literature
(Kishnani, Steiner et al., 2006; Slonim et al., 2000). For instance,
homozygous variants c.1843G>A, c.1933G>A, and 1935C>A, typi-
cally found in classic infantile Pompe disease, were reported in both
Groups A and B (Table 6). Upon careful review, the patients in Group
B appear to have had cardiomyopathy reported in the Registry after
12 months of age.
With regard to the frequencies of individual variants globally, it
must be noted that the figures are determined by the commonness of
certain variants in ethnic groups and by the number of patients that
were diagnosed in the specified geographic regions. Among all
variants reported in the Registry, the leaky splice site variant c.‐32‐
13T>G was by far the most common. This variant is found mostly in
regions where Caucasian populations are more abundant. Most of
the patients in the Pompe Registry were Caucasian (71.2%) and from
Europe (58.0%). This variant typically is in 80–90% of adult
Caucasian patients as well as some children with slower progressive
forms of Pompe disease (Groups B and C) (Herbert, Cope, Li, &
Kishnani, 2018; M. Kroos et al., 2012; M. A. Kroos et al., 2007;
Musumeci et al., 2015; Reuser et al., 2018; van Capelle et al., 2016;
Zampieri et al., 2011). Of note, the Registry does not collect
information on ethnic origins, migrations, or other population
movements that would allow for more in‐depth interpretation. Also,
c.525del and c.2481+102_2646+31del are frequent among patients
in all three groups in Europe (comprised mainly of Caucasian
populations) and North American (comprised of populations of more
varied ethnic origins), but are not among the most common in the
other regions, with the exception for c.2481+102_2646+31del, which
is among the variants reported for Group A in Latin America (De
Filippi et al., 2014; M. Kroos et al., 2012; Reuser et al., 2018).
Populations in Latin America represent a number of different
ethnicities, with significant groups of Caucasian inheritance but also
significant contributions from African, Native American, and Asian
populations (Llerena et al., 2009). In this report, both the small
number of patients from Latin America, as well as a lack of confirmed
ethnic background information collected in the Pompe Registry,
would not allow for a more in‐depth analysis.
In Asia‐Pacific, c.1935C>A was reported most often, but was not
among the top five reported in other regions. Nevertheless, this
variant was the fourth most common globally due to the input of
patients from Asia‐Pacific where it accounted for nearly half of
reported variants in Group A. Not unexpectedly, c1726G>A also was
common in Group A in this region since c.1935C>A and c.1726G>A
are linked in cis in patients in the Asia‐Pacific. The variant is a
common pseudodeficiency variant that reduces the activity of GAA
substantially if present but does not lead to Pompe disease. The
variant does not occur alone but is always linked to c.2065G>A,
another variant not leading to disease‐causing GAA deficiency.
Interestingly, c.2065G>A should have been reported with minimally
the same frequency as c.1935C>A (Kumamoto et al., 2009;
Labrousse et al., 2010). However, the numbers for c.1726G>A and
c.2065G>A in the Pompe Registry may be underestimated, reflecting
the reporting physicians’ understanding that pseudodeficiency
variants are not pathogenic and, therefore, they may not report
them to the Registry. The same seems to be the case for c.271G>A,
another common pseudodeficiency variant in Pompe disease. It is
typically found in Caucasian populations and leads to a decreased
affinity of GAA for glycogen, but not to disease‐causing GAA
deficiency (Martiniuk, Bodkin, Tzall, & Hirschhorn, 1990).
Variant c.2560C>T, the most common globally, fourth in Europe,
and also first in North America and Latin America among the Group A
patients, derives its high ranking from its origin in northern Africa. It
was brought to North America as well as to Brazil through the slave
trade (Becker et al., 1998; Nino et al., 2013), explaining its high reported
frequency in North America and Latin America. Homozygosity among
Group A patients points to its very detrimental effect.
Despite the reported overall low frequency of c.340_341insT, this
variant seems to be common in Registry patients from the Middle
East region and gives rise to the classic infantile phenotype when
occurring in homozygotes.
4.2 | Limitations of the analysis
As with many types of data collection initiatives, there are associated
limitations to the use of information entered into registries, including
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the Pompe Registry. Physicians and their teams enter data
voluntarily with informed consent of patients. However, as noted,
healthcare teams at sites may not enter data into the Registry the
same or consistently or with the same level of detail or accuracy in
regard to information about the details of GAA sequence analysis.
Patient privacy has to be respected and guaranteed and in
accordance with the informed consent provided by patients. As a
result, only 53 of the 80 identified unique novel variants were
reported for patients who had provided updated informed consent to
allow the data to be submitted to a public database. Despite these
limitations, we believe that the distribution and sharing of informa-
tion contained in registries overall, and in the Pompe Registry
specifically, can contribute substantially to the understanding of rare
conditions like Pompe disease.
The study reported here does not provide the GAA genotype for
all patients, that is, the complete genotype–phenotype correlation,
which was not within the scope of this analysis. Such an analysis also
would not have provided the breadth of important data and
information shared here. However, we did analyze the genotype–
phenotype correlation in cases of homozygosity and propose that full
genotype–phenotype analyses be a focus of future studies as more
variant data are added to the Registry.
Admittedly, age may not be an ideal criterion for classification of
patients because Pompe disease is a clinical spectrum and results can
potentially be biased. Within the spectrum, severity is markedly
important for phenotypic characteristic of the disease. Only the most
severe phenotype can be clearly distinguished by enzyme activity
lower than 1% and cardiomyopathy before 12 months of age. Above
that threshold, the spectrum is much harder to be further subdivided
according to signs and symptoms and age due to differences in
assessments and clinical practice. Furthermore, correlations to
enzyme activity and other measurable parameters is also challenging
across the spectrum. However, classifying patients by age can still be
useful when investigating the association between variants and
phenotypes as they also depend on patient ages.
We acknowledge that in some instances, other reported data may
seem contradictory to what is known. This is due in part to the nature of
reporting results from observational data. For example, although CRIM
determination is only relevant for Group A, <5 patients in Group B were
classified as CRIM‐negative based on information entered on the
Registry CRF by the reporting site (Table 1). Determination of CRIM
status is important because CRIM‐negative patients completely lack
endogenous GAA enzyme and tend to respond less favorably to enzyme
replacement therapy (ERT) and/or develop higher antibody titers while
receiving ERT (Banugaria et al., 2011; Kishnani et al., 2010). By
definition, patients in Groups B and C should only be CRIM‐positive.
However, as noted previously, we do not know how CRIM status was
determined and entered into the Registry and can only provide the data
as reported. In addition, the homozygous substitution (missense) variants
c.1843G>A, c.1933G>A, and c.1935C>A, typically found in classic
infantile Pompe disease patients, were reported in both Groups A and
B (Table 6). Upon careful review, the patients in Group B appear to have
had cardiomyopathy reported in the Registry after 12 months of age and
are expected to be in Group A. The homozygous deletion (large) variant
c.2481+102_2646+31del, also typically found in classic infantile Pompe
disease, was reported in Group A as well as in Group C (Table 6). This
may reflect that information was reported incorrectly for the patients in
Group C or may be the result of a technical error in the genetic analysis.
Overall, we believe the number of misclassified patients is low.
Alternatively, unexpected results (i.e., variants reported in patients
not typically associated with a phenotype) may be correct and
suggest that other variants may contribute to a patient's disease
severity and manifestations.
4.3 | Data from the Pompe Registry and future
directions
In summary, data reported in the Pompe Registry provide insight
in the distribution of GAA variants across the globe and across the
clinical spectrum, add to the number and diversity of GAA variants
registered in public databases through published data sharing,
provide a first indication of the severity degree of these variants,
and assist in diagnostic practice and outcome prediction. Future
analyses of variant data from the Pompe Registry from larger
patient populations will add to our knowledge and understanding.
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